FROP-1 peptide-conjugated ultrasmall superparamagnetic nanoparticles as a targeted T1-weighted MR contrast agent for breast cancer: in vitro study
It was found that the contrast intensity of the Fe<sub>3</sub>O<sub>4</sub>@FROP-1 nanoprobe increases as Fe concentration increases. Cellular uptake of the Fe<sub>3</sub>O<sub>4</sub> and Fe<sub>3</sub>O<sub>4</sub>@FROP-1 NPs was quantified using ICP-MS. The synthesized NPs had better imaging performance than Dotarem (gadoterate meglumine). The findings showed that Fe<sub>3</sub>O<sub>4</sub>@FROP-1 NPs have potential utility as a specific and targeted T1-weighted contrast agent in breast cancer MR imaging.
Authors
- Vahid Pirhajati Mahabadi (ORCID: https://orcid.org/0000-0002-7461-6559)
- Abolfazl Sarikhani
- Habib Ghaznavi (ORCID: https://orcid.org/0000-0002-4629-1697)
- Zahra Alamzadeh
- Rasoul Irajirad (ORCID: https://orcid.org/0000-0001-8555-2442)
- Samideh Khoei (ORCID: https://orcid.org/0000-0001-9357-0229)
- Melika Samari
Institutions
- Iran University of Medical Sciences (IR)
Publication Details
- Journal
- BMC Biomedical Engineering
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1186/s42490-025-00091-7
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Iran University of Medical Sciences
- Zahedan University of Medical Sciences